{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:31Z","timestamp":1793082751535,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507204"],"award-info":[{"award-number":["2023YFC2507204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179399","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:22:11Z","timestamp":1791472931000},"page":"179399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling"],"prefix":"10.1016","volume":"1037","author":[{"given":"Jianwei","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-0167","authenticated-orcid":false,"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179399_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ejphar.2026.179399_bib2","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-11-0004","article-title":"Anaplastic lymphoma kinase in human cancer","volume":"47","author":"Barreca","year":"2011","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.179399_bib3","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American heart association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.179399_bib5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/bcp.15158","article-title":"Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism","volume":"88","author":"Cheong","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1124\/dmd.119.086918","article-title":"Systematic development and verification of a physiologically based pharmacokinetic model of rivaroxaban","volume":"47","author":"Cheong","year":"2019","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.ejphar.2026.179399_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","article-title":"Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism","volume":"5","author":"Coleman","year":"2023","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib8","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.179399_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejphar.2026.179399_bib11","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.179399_bib13","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.123.001384","article-title":"Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions","volume":"53","author":"Foti","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.179399_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/03007995.2022.2070379","article-title":"Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: subanalysis of j'xactly","volume":"38","author":"Fukamachi","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2026.179399_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/bdd.1771","article-title":"Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice","volume":"33","author":"Grillo","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejphar.2026.179399_bib16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","article-title":"Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug\u2013drug interaction study in patients with ALK+ advanced tumors","volume":"87","author":"Hurtado","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jcph.1044","article-title":"Minimal physiologically based pharmacokinetic and drug-drug-disease interaction model of rivaroxaban and verapamil in healthy and renally impaired subjects","volume":"58","author":"Ismail","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2026.179399_bib21","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.179399_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1208\/s12248-016-0009-9","article-title":"Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and Co-medication regimens","volume":"19","author":"Moj","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2026.179399_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.179399_bib25","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/psp4.12844","article-title":"Application of physiologically\u2010based pharmacokinetic model approach to predict pharmacokinetics and <scp>drug\u2013drug<\/scp> interaction of rivaroxaban: a case study of rivaroxaban and carbamazepine","volume":"11","author":"Ngo","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib26","unstructured":"Open Systems Pharmacology. Accessed November 9, 2024. https:\/\/github.com\/Open\u2010Systems\u2010Pharmacology\/Fluconazole\u2010Model."},{"key":"10.1016\/j.ejphar.2026.179399_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0004-2022","article-title":"Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer","volume":"31","author":"Otten","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2026.179399_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2016.06.033","article-title":"Epidemiology of venous thromboembolism in the Framingham heart study","volume":"145","author":"Puurunen","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2026.179399_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28052254","article-title":"Generic methods for simultaneous analysis of four direct oral anticoagulants in human plasma and urine by ultra-high performance liquid chromatography-tandem mass spectrometry","volume":"28","author":"Ren","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.179399_bib30","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179399_bib32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ejphar.2026.179399_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/JTO.0b013e31811ea275","article-title":"High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients","volume":"2","author":"Tagalakis","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib34","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/psp4.13036","article-title":"Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: a first step for larger use of a priori modeling approach at bed side","volume":"12","author":"Terrier","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179399_bib35","series-title":"Physiologically Based Pharmacokinetic Analyses \u2014 Format and Content Guidance for Industry","year":"2018"},{"key":"10.1016\/j.ejphar.2026.179399_bib36","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib37","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/dmd.122.000928","article-title":"Inhibition of cytochrome P450 2J2-Mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib","volume":"50","author":"Wang","year":"2022","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.ejphar.2026.179399_bib38","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179399_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10557-020-07129-z","article-title":"Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant","volume":"36","author":"Zhao","year":"2022","journal-title":"Cardiovasc. Drugs Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:33:49Z","timestamp":1793079229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926008812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0014299926008812"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179399","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179399"}}